KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Deferred Revenue (2016 - 2020)

Nektar Therapeutics has reported Current Deferred Revenue over the past 11 years, most recently at $2.6 million for Q4 2020.

  • Quarterly results put Current Deferred Revenue at $2.6 million for Q4 2020, down 68.34% from a year ago — trailing twelve months through Dec 2020 was $2.6 million (down 68.34% YoY), and the annual figure for FY2020 was $2.6 million, down 68.34%.
  • Current Deferred Revenue for Q4 2020 was $2.6 million at Nektar Therapeutics, down from $3.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for NKTR hit a ceiling of $38.0 million in Q4 2017 and a floor of $2.6 million in Q4 2020.
  • Median Current Deferred Revenue over the past 5 years was $15.8 million (2016), compared with a mean of $16.1 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 164.56% in 2017 and later crashed 85.28% in 2020.
  • Nektar Therapeutics' Current Deferred Revenue stood at $14.4 million in 2016, then skyrocketed by 164.56% to $38.0 million in 2017, then plummeted by 35.12% to $24.6 million in 2018, then crashed by 67.24% to $8.1 million in 2019, then tumbled by 68.34% to $2.6 million in 2020.
  • The last three reported values for Current Deferred Revenue were $2.6 million (Q4 2020), $3.0 million (Q3 2020), and $4.3 million (Q2 2020) per Business Quant data.